Shi‐Xun Lu
Impact in
-
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
-
- Cancer-related molecular mechanisms research
Papers in
- Oncology 14
- Cancer Immunotherapy and Biomarkers 5
- Colorectal Cancer Screening and Detection 3
- Colorectal Cancer Treatments and Studies 2
- Pancreatic and Hepatic Oncology Research 2
-
- Genetic factors in colorectal cancer 6
- Co-authors
- Jing‐Ping YunMiao‐Zhen QiuFeng‐Hua WangWen‐Long GuanCaiyun HeYuhong LiRui‐Hua XuChris Zhiyi Zhang
- Journals
- Clinical & Translational Oncology (1 paper)British Journal of Cancer (1 paper)Nature Communications (1 paper)Frontiers in Immunology (1 paper)BMC Cancer (1 paper)
- Partner nations
- ChinaUnited StatesHong Kong
In The Last Decade
Shi‐Xun Lu
21 papers receiving 273 citations
Peers
Comparison fields: 5 of 36
- Oncology 120
- Cancer Research 64
- Gastroenterology 18
- Pulmonary and Respiratory Medicine 96
- Hepatology 23
Countries citing papers authored by Shi‐Xun Lu
This map shows the geographic impact of Shi‐Xun Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shi‐Xun Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shi‐Xun Lu more than expected).
Fields of papers citing papers by Shi‐Xun Lu
This network shows the impact of papers produced by Shi‐Xun Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shi‐Xun Lu. The network helps show where Shi‐Xun Lu may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shi‐Xun Lu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 9 | |
| 2 | 2023 | 56 | |
| 3 | 2023 | 4 | |
| 4 | 2023 | 9 | |
| 5 | 2023 | 5 | |
| 6 | 2022 | 12 | |
| 7 | 2022 | 12 | |
| 8 | 2022 | 11 | |
| 9 | 2022 | 12 | |
| 10 | 2021 | 18 | |
| 11 | 2021 | 11 | |
| 12 | PD-1 antibody camrelizumab for Epstein-Barr virus-positive metastatic gastric cancer: a single-arm, open-label, phase 2 trial. | 2021 | 32 |
| 13 | 2020 | 2 | |
| 14 | 2020 | 4 | |
| 15 | 2020 | 15 | |
| 16 | 2019 | 8 | |
| 17 | 2019 | 18 | |
| 18 | 2018 | 13 | |
| 19 | 2017 | 2 | |
| 20 | 2013 | 22 |
About Shi‐Xun Lu
Shi‐Xun Lu is a scholar working on Oncology, Pathology and Forensic Medicine, Hepatology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 21 papers that have together received 277 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (7 papers), Genetic factors in colorectal cancer (6 papers), Cancer Immunotherapy and Biomarkers (5 papers), Hepatocellular Carcinoma Treatment and Prognosis (3 papers), Metastasis and carcinoma case studies (3 papers), Colorectal Cancer Screening and Detection (3 papers), Colorectal Cancer Treatments and Studies (2 papers) and Pancreatic and Hepatic Oncology Research (2 papers). The work is most often cited by research in Oncology (120 citations), Cancer Research (64 citations), Gastroenterology (18 citations), Pulmonary and Respiratory Medicine (96 citations) and Hepatology (23 citations). Shi‐Xun Lu has collaborated with scholars based in China, United States and Hong Kong. Frequent co-authors include Jing‐Ping Yun, Miao‐Zhen Qiu, Feng‐Hua Wang, Wen‐Long Guan, Caiyun He, Yuhong Li, Rui‐Hua Xu, Chris Zhiyi Zhang, Leilei Chen and Tin Lok Wong. Their work appears in journals such as Clinical & Translational Oncology, British Journal of Cancer, Nature Communications, Frontiers in Immunology and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.